Intuitively, it would seem that GLP-1 use for obesity would reduce overall medical costs despite the increase in drug ...

There are more than 300 GLP-1Rs in an active stage of development, from industry giants and potential market disrupters.

This could start to bring down the cost of brand-name competitors—here's who may get to use it, and one major difference from ...

A new study finds semaglutide is linked to an increased risk of vision loss associated with a rare eye condition, but cases ...

Weight loss tops many folks' list of New Year's resolutions, and lots of people are turning to cutting-edge weight-loss drugs ...

What happened with Novo Nordisk stock? On Dec. 20, Novo announced results from a phase 3 clinical trial surrounding one of ...

The following is a summary of “Association of Perioperative Glucagon-like Peptide-1 Receptor Agonist Use and Postoperative ...

The Danish Medicines Agency requested the EMA's Pharmacovigilance Risk Assessment Committee review reports on the ...

These weight management drugs, which mimic natural hormones that regulate insulin and glucose levels, have become increasingly popular due to their effectiveness in promoting weight loss. However, ...

Insurers said one major driver of higher premiums is the growing popularity of a relatively new class of injectable drugs to ...

Ozempic has fast become a household name. In addition to helping people with diabetes manage their blood sugar levels, this ...

These drugs, called glucagon-like peptide-1 receptor agonists (GLP-1 RAs), work in several different ways to help people lose ...